Greg W wrote -Dear Friends and Supporters David was diagnosed last year with Duchenne muscular dystrophy, a fatal genetic disorder characterized by progressive muscle degeneration and weakness. Thankfully, DMD is slowly progressive, and David is having a great time at this stage in his life just being a wonderful, playful, caring little boy going to preschool. Scientists and drug companies are on the cusp of breakthrough discoveries with a total of 31 compounds under investigation in boys with Duchenne up from zero only 10 years ago. In fact, four of these drugs are in phase 3 clinical testing and could theoretically benefit David if approved. Recently, however, the FDA has rejected two out of the four drugs. Also, although these first generation therapies showed some promise in slowing the progression of disease, none of these is a cure. Clearly, given these setbacks, more funding is needed for early stage preclinical therapies. There is very promising early stage research going on in gene replacement therapy and gene editing therapy. Many investigational compounds would not progress to human trials without external support from Cure Duchenne, and that's where you can help. With your donation on this page (every dollar counts), we can raise money to cure Duchenne muscular dystrophy and potentially make a dramatic impact in the natural expected course of David's life, allowing him to stand longer, walk longer, and live longer. With your help, we can change the bleak future for David and the many boys who have DMD. All donations are fully tax deductible as Cure Duchenne is a 501(c)(3) non-profit tax-exempt organization. If you work for a large company, they may be able to match your contribution. About DMD: Duchenne muscular dystrophy is the most common fatal genetic disorder diagnosed in childhood, affecting approximately 1 in every 3,500 live male births (about 20,000 new cases each year worldwide). Duchenne typically has a loss of ambulation between ages 7 and 15 requiring use of an electric wheelchair, slow loss of upper extremity function in the teens, and early death due to cardiac or respiratory failure in 20s or 30s. The short life expectancy and grueling constant care, therapy and treatment for the disorder are heartbreaking.